Navigation Links
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008
Date:1/12/2009

VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX:QLT) today announced global Visudyne(R) (verteporfin) sales of US$30.6 million for the quarter and $141.9 million for the full year ended December 31, 2008. Visudyne sales for the fourth quarter declined by 32.7% over the same quarter in 2007 and the full year represented a decrease of 34.0% from annual sales in 2007. Sales in the U.S. for the quarter were $8.0 million, down 20.0% from the prior-year fourth quarter while sales outside the U.S. were $22.6 million, down 36.3% from the same quarter of the prior year.

QLT will release its full financial results on Thursday, February 19, 2009, at 7:30 AM Eastern Time (ET).

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is set out in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

Conference call information

QLT Inc. will hold an investor conference call to discuss fourth quarter and year end 2008 results on Thursday, February 19, 2009 at 8:30 a.m. EST (5:30 a.m. PST). The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. EST. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "number" sign.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at www.qltinc.com.

    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
    Atrigel is a registered trademark of QLT USA, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-aventis.

    QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."


'/>"/>
SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranir, LLC Announces the Acquisition of Placontrol, Inc.
2. Varian Medical Systems Announces Net Orders Growth Estimates for the First Quarter of Fiscal Year 2009
3. Mindray Announces Preliminary 2008 Operating Results
4. BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
5. Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue
6. Allen Technologies, Inc. Announces Vigo Interactive Communication and Education System Agreement with Saint John's Health Center, Santa Monica, California
7. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
8. Oleen Pinnacle Announces Acquisition of Partners in Health Systems
9. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
10. Miami Beach Real Estate Attorney Announces Specialized Legal and Realty Services for Clients Buying Bank-Owned Luxury Miami Beach Condos
11. Genomma Lab Announces Initiation of Stock Repurchase Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, ... members and suppliers for its inaugural Member Conference at the Paris Hotel in ... elevating the operational health of America’s healthcare providers. , The conference was highlighted ...
(Date:5/26/2016)... Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and healing, ... three core values: Meaningful Life in a Real Home provided by Empowered Staff. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
Breaking Medicine Technology: